BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 11324764)

  • 1. Treatment of metastatic renal cell carcinoma with high-dose bolus interleukin-2 in a non-intensive care unit: an analysis of 124 consecutively treated patients.
    Gitlitz BJ; Hoffman DM; Moldawer N; Belldegrun A; Figlin RA
    Cancer J; 2001; 7(2):112-20. PubMed ID: 11324764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
    Dutcher JP; Logan T; Gordon M; Sosman J; Weiss G; Margolin K; Plasse T; Mier J; Lotze M; Clark J; Atkins M
    Clin Cancer Res; 2000 Sep; 6(9):3442-50. PubMed ID: 10999727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma.
    Thompson JA; Shulman KL; Benyunes MC; Lindgren CG; Collins C; Lange PH; Bush WH; Benz LA; Fefer A
    J Clin Oncol; 1992 Jun; 10(6):960-8. PubMed ID: 1588376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report.
    Yang JC; Topalian SL; Parkinson D; Schwartzentruber DJ; Weber JS; Ettinghausen SE; White DE; Steinberg SM; Cole DJ; Kim HI
    J Clin Oncol; 1994 Aug; 12(8):1572-6. PubMed ID: 8040669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.
    Fyfe G; Fisher RI; Rosenberg SA; Sznol M; Parkinson DR; Louie AC
    J Clin Oncol; 1995 Mar; 13(3):688-96. PubMed ID: 7884429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2: a single-center phase II study.
    Geertsen PF; Hermann GG; von der Maase H; Steven K
    J Clin Oncol; 1992 May; 10(5):753-9. PubMed ID: 1569448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma.
    Atkins MB; Sparano J; Fisher RI; Weiss GR; Margolin KA; Fink KI; Rubinstein L; Louie A; Mier JW; Gucalp R
    J Clin Oncol; 1993 Apr; 11(4):661-70. PubMed ID: 8478661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of systemic versus inhaled recombinant IL-2 administration for the treatment of metastatic renal cell carcinoma.
    Huland E; Heinzer H; Huland H
    Folia Biol (Praha); 2000; 46(6):241-50. PubMed ID: 11140857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of the number of treatment courses on the clinical response of patients who receive high-dose bolus interleukin-2.
    Lindsey KR; Rosenberg SA; Sherry RM
    J Clin Oncol; 2000 May; 18(9):1954-9. PubMed ID: 10784637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcome of high-dose bolus intravenous interleukin-2 with a modified administration schedule for Asian patients with metastatic renal cell carcinoma.
    Lee JY; Song C; Hong BS; Hong JH; Ahn H; Lee JL
    Cancer Chemother Pharmacol; 2017 Jan; 79(1):173-180. PubMed ID: 28011979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II trial of dose-intensive interleukin-2 in metastatic renal cell carcinoma.
    Oleksowicz L; Dutcher JP
    J Cancer Res Clin Oncol; 1999; 125(2):101-8. PubMed ID: 10190317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer.
    Acquavella N; Kluger H; Rhee J; Farber L; Tara H; Ariyan S; Narayan D; Kelly W; Sznol M
    J Immunother; 2008; 31(6):569-76. PubMed ID: 18528297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy of pulmonary metastatic renal cell carcinoma: success dependant on risk factors?
    Huland E; Heinzer H; Huland H
    Hepatogastroenterology; 1999 May; 46 Suppl 1():1257-62. PubMed ID: 10429971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical study on recombinant human interleukin-2 (Proleukin) in the treatment of metastatic renal cell carcinoma].
    Sheng XN; Li JL; Guo J; Zhao XH; Zhu J; Chu DT
    Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):129-33. PubMed ID: 18646697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of continuous infusion plus pulse interleukin-2 with famotidine in patients with metastatic kidney cancer or melanoma previously treated with interleukin-2.
    Quan WD; Walker PR; Quan FM; Ramirez M; Elsamaloty HM; Ghai V; Vinogradov M; Liles DK
    Cancer Biother Radiopharm; 2006 Oct; 21(5):437-42. PubMed ID: 17105418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe.
    Negrier S; Maral J; Drevon M; Vinke J; Escudier B; Philip T
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S93-8. PubMed ID: 10685667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose continuous intravenous infusion of interleukin-2 therapy for metastatic renal cell carcinoma: the University of Chicago experience.
    Shulman KL; Stadler WM; Vogelzang NJ
    Urology; 1996 Feb; 47(2):194-7. PubMed ID: 8607232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Five-year survival results of subcutaneous low-dose immunotherapy with interleukin-2 alone in metastatic renal cell cancer patients.
    Bordin V; Giani L; Meregalli S; Bukovec R; Vaghi MM; MandalĂ  M; Paolorossi F; Ardizzoia A; Tancini G; Barni S; Frigerio F; Fumagalli L; Bordoni A; Valsuani G; Di Felice G; Lissoni P
    Urol Int; 2000; 64(1):3-8. PubMed ID: 10782024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer.
    Kammula US; White DE; Rosenberg SA
    Cancer; 1998 Aug; 83(4):797-805. PubMed ID: 9708948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of sequential low-dose 5-aza-2'-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma.
    Gollob JA; Sciambi CJ; Peterson BL; Richmond T; Thoreson M; Moran K; Dressman HK; Jelinek J; Issa JP
    Clin Cancer Res; 2006 Aug; 12(15):4619-27. PubMed ID: 16899610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.